Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

David P. Ryan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9685-673X; OpenAlex author ID A5070720153, A5103496544, A5103688917. Sources: ClinicalTrials.gov.

Their work

Papers
52 (first author 5, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
184
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 3 papers · 2014: 6 papers, 1 trial · 2015: 3 papers · 2016: 1 paper · 2017: 4 papers · 2018: 3 papers · 2019: 4 papers · 2020: 5 papers · 2021: 5 papers · 2022: 7 papers · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 3 papers

Papers 50 of 52

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  3. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  4. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  5. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  6. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  7. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  8. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-22-1630↗
  9. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemor… Co-author DOI 10.1007/s00330-021-08304-y↗
  10. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  11. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  12. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  13. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  14. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  15. Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. Co-author DOI 10.1200/op.22.00088↗
  16. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Co-author DOI 10.1007/s11307-020-01569-7↗
  17. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  18. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Co-author DOI 10.1038/s43018-021-00269-7↗
  19. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  20. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Co-author DOI 10.21037/jgo-21-197↗
  21. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-l… Co-author DOI 10.1007/s10637-019-00830-3↗
  22. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Co-author DOI 10.1016/j.pan.2020.03.011↗
  23. Pancreatic Cancer: A Time to Change. First author DOI 10.1097/sla.0000000000003910↗
  24. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004200↗
  25. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  26. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  27. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  28. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  29. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Co-author DOI 10.1634/theoncologist.2018-0114↗
  30. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical … Co-author DOI 10.1001/jamaoncol.2018.0329↗
  31. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000336↗
  32. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Ca… Co-author DOI 10.1097/coc.0000000000000349↗
  33. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Co-author DOI 10.1097/mpa.0000000000000731↗
  34. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-0256↗
  35. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. Co-author DOI 10.1371/journal.pone.0182855↗
  36. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Panc… Last author DOI 10.1634/theoncologist.2017-0472↗
  37. Understanding the Paradigm Shift in Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.017079↗
  38. Predicting a response to FOLFIRINOX in pancreatic cancer. First author DOI 10.1093/jnci/djv175↗
  39. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗
  40. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Last author DOI 10.1200/jco.2014.55.7504↗
  41. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable … First author DOI 10.1016/j.ijrobp.2014.03.034↗
  42. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage I… Co-author DOI 10.1016/j.pan.2014.07.003↗
  43. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Co-author DOI 10.1016/j.prro.2013.07.006↗
  44. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2013.10.027↗
  45. Pancreatic adenocarcinoma. Co-author DOI 10.1056/nejmc1412266↗
  46. Pancreatic adenocarcinoma. Co-author DOI 10.1056/nejmra1404198↗
  47. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at… Co-author DOI 10.1002/cncr.28329↗
  48. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Co-author DOI 10.1097/sla.0b013e318263da2f↗
  49. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Co-author DOI 10.1634/theoncologist.2012-0435↗
  50. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. First author DOI 10.1002/cncr.26633↗

Trials 1

  1. Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Principal investigator NCT02243007↗

Closest collaborators

The 25 strongest of 184 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Sunki Hong · 39 shared papers, 2011–2026 · strength 3.56
  2. Jennifer Yon-Li Wo · 29 shared papers, 2012–2026 · strength 2.82
  3. Keith D. Lillemoe · 24 shared papers, 2013–2026 · strength 2.27
  4. Cristina Rosa Ferrone · 25 shared papers, 2013–2024 · strength 2.21
  5. Colin D. Weekes · 15 shared papers, 2019–2026 · strength 1.97
  6. Lawrence Scott Blaszkowsky · 23 shared papers, 2011–2026 · strength 1.82
  7. Motaz Qadan · 13 shared papers, 2019–2026 · strength 1.68
  8. Carlos F. Fernandez-del Castillo · 20 shared papers, 2011–2023 · strength 1.44
  9. David Tsai Ting · 14 shared papers, 2015–2026 · strength 1.39
  10. Carlos Fernández-del Castillo · 12 shared papers, 2013–2026 · strength 1.25
  11. Aparna R. Parikh · 9 shared papers, 2019–2026 · strength 1.08
  12. Andrew Louis Warshaw · 9 shared papers, 2013–2023 · strength 0.70
  13. Ryan David Nipp · 8 shared papers, 2015–2022 · strength 0.66
  14. Vikram Deshpande · 9 shared papers, 2013–2022 · strength 0.62
  15. Eunice Lee Kwak · 14 shared papers, 2011–2019 · strength 0.58
  16. Hannah Johnson Roberts · 3 shared papers, 2024–2026 · strength 0.55
  17. Janet E. Murphy · 8 shared papers, 2013–2022 · strength 0.51
  18. Alec C. Kimmelman · 4 shared papers, 2022–2024 · strength 0.48
  19. Brian Matthew Wolpin · 5 shared papers, 2012–2026 · strength 0.46
  20. Theodoros P. Michelakos · 5 shared papers, 2017–2022 · strength 0.46
  21. Jin Peng He · 4 shared papers, 2020–2024 · strength 0.45
  22. Toni T. Seppälä · 4 shared papers, 2020–2024 · strength 0.45
  23. Richard Andrew Burkhart · 4 shared papers, 2020–2024 · strength 0.45
  24. Reecha Suri · 4 shared papers, 2020–2024 · strength 0.45
  25. Elizabeth M. Jaffee · 4 shared papers, 2020–2024 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.